AZN

NASDAQ:AZN

AstraZeneca plc

Add to Watchlist
  • Stock

10,648.00

+0.38%

40.00

USD last updated 28/07 01:48:46

Last Close

10,608.00

02/05 08:36

Market Cap

1.88B

Beta: 0.17

Volume Today

322.06K

Avg: 4.68M

PE Ratio

34.25

PFCF: 28.96

Dividend Yield

2.22%

Payout:75.97%

This week's key economic and corporate events include the Federal Reserve's interest-rate decision, a critical tariffs deadline, July jobs report, inflation data, and earnings reports from major companies like Microsoft, Meta, Apple, and Amazon. Market participants are closely watching trade negotiations, economic indicators, and corporate performance to gauge potential shifts in policy and market trends.

investopedia.com

AstraZeneca and Arcus Biosciences are conducting a Phase III clinical trial to evaluate the efficacy of combining durvalumab and domvanalimab in treating Stage III unresectable non-small cell lung cancer (NSCLC). The study, which began in 2022 and is projected to complete in 2025, employs a randomized, double-blind design with quadruple masking to ensure unbiased results. Positive outcomes could impact the companies' stock performance in the oncology sector.

theglobeandmail.com

The article discusses Astrazeneca's stock performance, upcoming earnings, financial metrics, and industry rankings. It highlights the company's stock decline relative to broader market indices, projected earnings, Zacks Rank, and key financial ratios like P/E and PEG.

finance.yahoo.com

Bristol Myers Squibb (BMY) appointed Dr. Cristian Massacesi as executive vice president, chief medical officer, and head of development, effective August 1, 2025. Dr. Massacesi previously led AstraZeneca’s global medical organization, overseeing 150+ clinical studies and regulatory approvals, and held senior R&D roles at Pfizer and Novartis.

thepharmaletter.com

AstraZeneca (AZN) is predicted to report Q2 earnings of $1.09 per share, a 10.1% increase from the same period last year, with revenues forecasted at $14.03 billion, representing an 8.4% year-over-year growth. Analysts provided detailed projections for key product lines, including Symbicort-World ($725.73M, +0.5%), Pulmicort-World ($131.45M, -15.2%), and Tagrisso-U.S. ($719.97M, +9.4%). The stock has risen 4.8% in the past month, compared to the S&P 500's 5.7% gain, with a Zacks Rank #3 (Hold) indicating cautious optimism.

nasdaq.com

    Description

    AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/F...Show More

    Earnings

    Earnings per Share (Estimate*)

    0.20.40.60.811.22018-02-022020-02-142022-02-102024-02-082025-02-13

    Revenue (Estimate*)

    2B4B6B8B10B12B2018-02-022020-02-142022-02-102024-02-082025-02-13

    *Estimate based on analyst consensus